Swiss National Bank
FATE icon

Swiss National Bank’s Fate Therapeutics FATE Stock Holding History

Swiss National Bank’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-166,700
Closed -$583K – 2454
2024
Q3 		$583K Sell
166,700
-12,400
-7% -$48.3K ﹤0.01% 2399
2024
Q2 		$587K Buy
+179,100
New +$784K ﹤0.01% 2382
2023
Q4 		– Sell
-171,000
Closed -$363K – 2566
2023
Q3 		$363K Hold
171,000
– – ﹤0.01% 2564
2023
Q2 		$814K Buy
171,000
+3,200
+2% +$17.7K ﹤0.01% 2397
2023
Q1 		$956K Sell
167,800
-19,600
-10% -$118K ﹤0.01% 2280
2022
Q4 		$1.89M Buy
187,400
+4,100
+2% +$77K ﹤0.01% 1931
2022
Q3 		$4.11M Buy
183,300
+1,600
+0.9% +$46.2K ﹤0.01% 1391
2022
Q2 		$4.5M Buy
181,700
+1,100
+0.6% +$30.4K ﹤0.01% 1376
2022
Q1 		$7M Buy
180,600
+13,100
+8% +$507K ﹤0.01% 1229
2021
Q4 		$9.8M Buy
167,500
+1,300
+0.8% +$73.7K 0.01% 1023
2021
Q3 		$9.85M Buy
166,200
+800
+0.5% +$62.8K 0.01% 1013
2021
Q2 		$14.4M Buy
165,400
+6,000
+4% +$483K 0.01% 832
2021
Q1 		$13.1M Buy
159,400
+2,300
+1% +$220K 0.01% 853
2020
Q4 		$14.3M Buy
157,100
+16,200
+11% +$1.01M 0.01% 763
2020
Q3 		$5.63M Buy
140,900
+6,000
+4% +$210K ﹤0.01% 1099
2020
Q2 		$4.63M Buy
134,900
+17,600
+15% +$525K ﹤0.01% 1191
2020
Q1 		$2.6M Buy
117,300
+4,000
+4% +$101K ﹤0.01% 1291
2019
Q4 		$2.22M Buy
113,300
+2,400
+2% +$38.1K ﹤0.01% 1669
2019
Q3 		$1.72M Buy
110,900
+14,800
+15% +$284K ﹤0.01% 1754
2019
Q2 		$1.95M Buy
96,100
+2,100
+2% +$37.8K ﹤0.01% 1707
2019
Q1 		$1.65M Buy
94,000
+5,300
+6% +$83.7K ﹤0.01% 1787
2018
Q4 		$1.14M Buy
88,700
+2,300
+3% +$32.1K ﹤0.01% 1927
2018
Q3 		$1.41M Buy
86,400
+12,900
+18% +$153K ﹤0.01% 1944
2018
Q2 		$833K Buy
+73,500
New +$810K ﹤0.01% 2269

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Swiss National Bank's FATE Position: Q4 2024 in Review

Swiss National Bank sold out of Fate Therapeutics (FATE) in Q4 2024, closing a stake of 166,700 shares — an estimated $583K sold.

Swiss National Bank first reported a position in FATE in Q2 2018 and held it in 24 quarters. The position peaked at $14.4M in Q2 2021. 159 funds tracked by Wall St. Rank hold FATE as of Q4 2024.

  • Swiss National Bank reported no remaining Fate Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Swiss National Bank sold 166,700 Fate Therapeutics shares in Q4 2024, an estimated $583K.
  • Swiss National Bank first reported a position in Fate Therapeutics in Q2 2018 and held it in 24 quarters.
  • Swiss National Bank's Fate Therapeutics position peaked at $14.4M in Q2 2021.
  • 159 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2024.

Based on Swiss National Bank's 13F filing for Q4 2024, filed 10 Feb 2025.